| アブストラクト | INTRODUCTION: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with an increased risk of gallbladder and bile duct disease among patients with type 2 diabetes. METHODS: We conducted a population-based cohort study using an active comparator, new-user design. We used data from the United Kingdom Clinical Practice Research Datalink to identify patients newly treated with either a DPP-4 inhibitor or sodium-glucose cotransporter-2 (SGLT-2) inhibitor between January 2013 and December 2020. We fitted Cox proportional hazards models with propensity score fine stratification weighting to estimate the hazard ratio (HR) and its 95% confidence interval (CI) for incident gallbladder and bile duct disease associated with DPP-4 inhibitors compared to SGLT-2 inhibitors. RESULTS: DPP-4 inhibitors were associated with a 46% increased risk of gallbladder and bile duct disease (4.3 vs. 3.0 events per 1000 person-years, HR 1.46, 95% CI 1.17-1.83). At 6 months and 1 year, 745 and 948 patients, respectively, would need to be treated with DPP-4 inhibitors for one patient to experience a gallbladder or bile duct disease. CONCLUSIONS: In this population-based cohort study, the use of DPP-4 inhibitors, when compared with SGLT-2 inhibitors, was associated with a moderately increased risk of gallbladder and bile duct disease among patients with type 2 diabetes. This outcome was still quite rare with a high number needed to harm at 6 months and 1 year. |
|---|
| 組織名 | Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;3755 Cote Sainte-Catherine, H425.1, Montreal, H3T 1E2, Canada.;Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, H3A 1G1, Canada.;Division of Endocrinology, Jewish General Hospital, Montreal, H3T 1E2, Canada.;laurent.azoulay@mcgill.ca.;University, Montreal, H3A 1G1, Canada. laurent.azoulay@mcgill.ca.;Gerald Bronfman Department of Oncology, McGill University, Montreal, H4A 3T2,;Canada. laurent.azoulay@mcgill.ca. |
|---|
